XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue Recognition - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Disaggregation Of Revenue [Line Items]        
Payment period from distributors received from date of sale     45 days  
Net loss per share basic [1] $ (0.05) $ (0.01) $ (0.13) $ (0.27)
Net loss per share-diluted [1] $ (0.05) $ (0.01) $ (0.13) $ (0.27)
Effect of significant financing component when transfer and customer payment of good or service occurs within one year or less     true  
Medicaid rebate        
Disaggregation Of Revenue [Line Items]        
Change in estimate recognized $ 6.5   $ 15.1  
Change in net income loss $ 6.5   $ 15.1  
Net loss per share basic $ (0.06)   $ (0.17)  
Net loss per share-diluted $ (0.06)   (0.17)  
Exclusion of licensing revenue change in estimate        
Disaggregation Of Revenue [Line Items]        
Net loss per share basic     (0.16)  
Net loss per share-diluted     $ (0.16)  
VASCEPA 1-Gram        
Disaggregation Of Revenue [Line Items]        
Product expiration date after being converted into capsule form     4 years  
VASCEPA 0.5-Gram        
Disaggregation Of Revenue [Line Items]        
Product expiration date after being converted into capsule form     3 years  
Edding        
Disaggregation Of Revenue [Line Items]        
Additional license revenues $ 5.0   $ 5.0  
HLS        
Disaggregation Of Revenue [Line Items]        
Additional license revenues $ 5.3   $ 5.3  
Minimum        
Disaggregation Of Revenue [Line Items]        
Sales discount percentage 2.00%   2.00%  
Maximum        
Disaggregation Of Revenue [Line Items]        
Sales discount percentage 3.00%   3.00%  
[1] Excluding the licensing revenue change in estimate and Medicaid change in estimate, both discussed in Note 7 – Revenue Recognition, net loss per share basic and diluted for the three and nine months ended September 30, 2023 would have been $(0.06) and $(0.19), respectively.